Summary: Use of escitalopram 10mg daily compared to placebo resulted in decreased pain severity and interference in a sample of opioid-dependent patients with depressive symptoms.Abstract: Pain is common among opioid-dependent patients, yet pharmacologic strategies are limited. The aim of this study was to explore whether escitalopram, a selective serotonin reuptake inhibitor, was associated with reductions in pain. The study used longitudinal data from a randomized, controlled trial that evaluated the effects of escitalopram on treatment retention in patients with depressive symptoms who were initiating buprenorphine/naloxone for treatment of opioid dependence. Participants were randomized to receive escitalopram 10mg or placebo daily. Changes in pain severity, pain interference, and depr…
Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms
Previous post: Buprenorphine/naloxone inhibition of remifentanil procedural sedation
Next post: Transfer from high dose methadone to buprenorphine/naloxone.